In another study, CEBPB enhances autophagy in prostate cancer cells by promoting autophagosome-lysosome fusion and inducing REDD1 expression, whereas its downregulation increases prostate cancer cell sensitivity to bortezomib (Barakat et al., 2016; Wang et al., 2019). Here, DDIT4 is linked to prostate cancer.